[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Scripps Health\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":170},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,45,72,97,118,147],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":28,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100646386","digital-and-plasma-biomarkers-in-delirium-100646386",false,"NCT07694206","Digital and Plasma Biomarkers in Delirium","Delirium Evaluation With Longitudinal Tau Assessment","DELTA","Inclusion Criteria:\n\n* Admitted to the intensive care unit\n* Able to consent or have a legally authorized representative consent on their behalf\n* English speaker\n* Expected ICU stay of 48 hours or more\n\nExclusion Criteria:\n\n* Advanced dementia\n* End stage liver disease\n* Renal replacement therapy\n* Structural brain injury, including but not limited to traumatic brain injury, cerebrovascular accident and intracranial hemorrhage,","ALL","65 Years",{"count":20,"type":21},100,"ESTIMATED","OBSERVATIONAL","The goal of this observational study is to learn if there are potential digital and plasma-based biomarkers that could help detect, predict, and prognosticate delirium in older adult patients who are admitted to the intensive care unit (ICU). The main question DELTA aims to answer is:\n\nCan digital biometrics predict and detect delirium in older adult ICU patients? Do biomarkers of neurodegeneration fluctuate in ICU patients in such a way that delrium could potentially be predicted?\n\nParticipants admitted o the ICU will wear a digital device to collect biometric data and will have serial plasma samples collected during ICU admission and patients will be also assessed for delirium daily by study staff.",[25,26,27],"Critical Illness","Delirium in the Intensive Care Unit","Sleep Quality",[29,30,31],"Sleep in the ICU","Delirium in the ICU","Delirium biomarkers","RECRUITING","2026-07-02",{"date":35,"type":36},"2026-07-09","ACTUAL",{"date":38,"type":36},"2026-05-28",{"date":40,"type":21},"2027-12-31",{"name":42,"class":43},"Scripps Health","OTHER",2,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":17,"minAge":53,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":56,"phases":57,"briefSummary":59,"conditions":60,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":71},"100561447","diagnostic-refinement-and-educational-approaches-in-managing-bone-marrow-transplantation-100561447","NCT06590285","Diagnostic Refinement and Educational Approaches in Managing Bone Marrow Transplantation","Diagnostic Refinement and Educational Approaches in Managing Bone Marrow Transplantation (DREAM-BMT)","DREAM-BMT","Inclusion Criteria:\n\n* Male or female patients aged 18 or older at the time of study informed consent.\n* Have plan to undergo alloHSCT from any donor source using bone marrow, peripheral blood stem cells, or cord blood. Recipients of non-myeloablative, myeloablative and reduced intensity conditioning are eligible.\n* Patients have access to digital device capable of downloading study app\n* Patients able to read study documents and able to complete informed consent within the study app\n\nExclusion Criteria:\n\n* Failed prior alloHSCT within the past 6 months","18 Years",{"count":55,"type":21},60,"INTERVENTIONAL",[58],"NA","This randomized, phase I\u002FII, open-label study will investigate the efficacy and safety of an educational sleep intervention vs standard of care in adults undergoing alloHSCT. The randomization target in this pilot phase is 60 patients.",[61,62],"GVHD","Bone Marrow Transplant Complications","2026-04-03",{"date":65,"type":36},"2026-04-09",{"date":67,"type":36},"2026-04-02",{"date":69,"type":21},"2033-11-01",{"name":42,"class":43},1,{"id":73,"slug":74,"hasResults":11,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":78,"eligibilityCriteria":79,"healthyVolunteers":11,"sex":17,"minAge":53,"maxAge":4,"enrollmentInfo":80,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":82,"conditions":83,"keywords":85,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":71},"100625266","non-invasive-detection-of-right-to-left-cardiac-shunts-100625266","NCT07420400","Non-Invasive Detection of Right-to-Left Cardiac Shunts","Novel Approach for the Detection of Right-to-Left Cardiac Shunts","HEADBAND","Undergoing clinically indicated TEE with bubble study for the detection of a PFO",{"count":81,"type":21},75,"This study will test the sensitivity of a novel, battery-powered, non-invasive ultrasound device to detect a right-to-left shunt",[84],"Patent Foramen Ovale (PFO)",[86,87,88],"PFO","Cryptogenic stroke","shunt","2026-02-12",{"date":91,"type":36},"2026-02-19",{"date":93,"type":36},"2026-01-07",{"date":95,"type":21},"2027-03-01",{"name":42,"class":43},{"id":98,"slug":99,"hasResults":11,"nctId":100,"briefTitle":101,"officialTitle":102,"acronym":4,"eligibilityCriteria":103,"healthyVolunteers":11,"sex":17,"minAge":53,"maxAge":4,"enrollmentInfo":104,"targetDuration":4,"studyType":56,"phases":106,"briefSummary":107,"conditions":108,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":110,"lastUpdatePostDateStruct":111,"startDateStruct":113,"completionDateStruct":115,"leadSponsor":117,"locationsCount":71},"100548465","closed-loop-spinal-cord-stimulation-for-complex-regional-pain-syndrome-100548465","NCT06421350","Closed Loop Spinal Cord Stimulation for Complex Regional Pain Syndrome","Efficacy of Closed-Loop Spinal Cord Stimulation for Complex Regional Pain Syndrome","Inclusion Criteria:\n\n* 18 years or older\n* neuromodulation naive patients with unilateral CRPS type 1 or type 2 (defined by Budapest Criteria)\n* pre-procedure psychological clearance\n\nExclusion Criteria:\n\n* younger than 18 years\n* prior neuromodulation including spinal cord stimulation\n* prior dorsal root ganglion stimulation\n* prior peripheral nervous system stimulation\n* anatomical obstacles to dorsal column lead placement",{"count":105,"type":21},32,[58],"The primary purpose of this study is to determine the differences in response to treatment of complex regional pain syndrome with a closed-loop spinal cord stimulator if applied in the early phases (acute or subacute) versus the chronic phase.",[109],"Complex Regional Pain Syndromes","2025-10-30",{"date":112,"type":36},"2025-11-03",{"date":114,"type":36},"2024-09-03",{"date":116,"type":21},"2026-06",{"name":42,"class":43},{"id":119,"slug":120,"hasResults":11,"nctId":121,"briefTitle":122,"officialTitle":122,"acronym":123,"eligibilityCriteria":124,"healthyVolunteers":11,"sex":17,"minAge":53,"maxAge":125,"enrollmentInfo":126,"targetDuration":4,"studyType":56,"phases":128,"briefSummary":131,"conditions":132,"keywords":134,"overallStatus":138,"whyStopped":4,"lastUpdateSubmitDate":139,"lastUpdatePostDateStruct":140,"startDateStruct":142,"completionDateStruct":144,"leadSponsor":146,"locationsCount":4},"100564601","phase-1-a-randomized-placebo-controlled-trial-of-prednisone-in-refractory-restless-legs-syndrome-a-pilot-study-100564601","NCT06631300","A Randomized, Placebo-controlled Trial of Prednisone in Refractory Restless Legs Syndrome: a Pilot Study","PrRLS","Inclusion Criteria:\n\n* Outpatient\n* Refractory RLS defined as restless legs unresponsive to monotherapy with tolerable doses of first-line agents due to reduction in efficacy, augmentation, or adverse effects\n* IRLS score greater than 15\n\nExclusion Criteria:\n\n* Pregnancy\n* Prescence of iron deficiency anemia\n* History of Diabetes Mellitus Type 1 and Type 2\n* History of uncontrolled hypertension\n* Presence of immunosuppression (HIV or currently taking immunosuppressants)\n* Any prior adverse reaction to glucocorticoids\n* History of dementia or major psychiatric diseases with psychosis\n* Lack of ability to understand the experimental protocol and to adequately communicate in English","80 Years",{"count":127,"type":21},50,[129,130],"PHASE1","PHASE2","Restless legs syndrome is a common sleep-related movement disorder that affects up to 15% of the population in North America, characterized by an uncomfortable urge to move the legs. This has been associated with poor quality of sleep and overall decreased quality of life. Chronic inflammation has been implicated as a key mediator of the low intracranial iron stores that characterize restless legs syndrome (RLS). Current medications for RLS target concomitant low serum iron levels or the dopaminergic pathway, but none target the inflammatory pathway. A novel therapy that focuses on inflammation would allow for additional research into the role of inflammation and cytokines in the development of RLS, and potentially unlock a new class of medications to treat patients with RLS. A small amount of prior evidence suggest that RLS symptoms improve with steroids, with associated improved quality of life, and with decreasing hepcidin levels as a biomarker of symptom severity. This pilot study, using an RCT design, serves to assess the efficacy of glucocorticoids in the alleviation of RLS symptoms, which would further anchor the association between RLS, inflammation, and one of its potential mediators - hepcidin. By giving a prednisone taper versus placebo, this study primarily aims to assess the effect of glucocorticoids on 1) decreasing RLS symptom severity. This study also aims to measure 2) objectively measured improvement in sleep, 3) changes in baseline and post-treatment hepcidin levels, and 4) prevalence of adverse events including psychosis and weight gain. RLS can be a debilitating disease and several non-traditional medications have been tested but with unequivocal results. Glucocorticoids may be an easily accessible and affordable key to better quality of life for RLS patients, especially those with refractory RLS.",[133],"Restless Legs Syndrome",[135,136,137],"refractory rls","rls","restless legs syndrome","NOT_YET_RECRUITING","2024-10-06",{"date":141,"type":36},"2024-10-08",{"date":143,"type":21},"2024-10-01",{"date":145,"type":21},"2025-12-31",{"name":42,"class":43},{"id":148,"slug":149,"hasResults":11,"nctId":150,"briefTitle":151,"officialTitle":152,"acronym":4,"eligibilityCriteria":153,"healthyVolunteers":11,"sex":17,"minAge":53,"maxAge":4,"enrollmentInfo":154,"targetDuration":4,"studyType":56,"phases":155,"briefSummary":156,"conditions":157,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":162,"lastUpdatePostDateStruct":163,"startDateStruct":165,"completionDateStruct":167,"leadSponsor":169,"locationsCount":71},"100475771","sleepless-at-scripps-an-inpatient-white-noise-study-100475771","NCT05475262","Sleepless at Scripps: An Inpatient White Noise Study","Sleepless at Scripps: The Use of White Noise to Increase Sleep Duration in Hospitalized Patients, a Prospective Study","Inclusion Criteria:\n\n* Over 18 years old\n* Admitted to inpatient internal medicine service for at least 3 nights\n\nExclusion Criteria:\n\n\\-",{"count":127,"type":21},[58],"Sleep is an important part of the healing process, and patients admitted to the hospital often report poor sleep. Patients have difficulty not only falling sleep, but also staying asleep. Prior studies show that hospital noise may be a contributing factor, and in particular, sound level changes (which refers to an increase in sound above the background\u002Fbaseline noise level) may cause arousals from sleep. Based on preliminary data, this study aims to use white noise to reduce the number of relevant sound level changes that occur during a night of sleep in the hospital. Using a randomized, cross-over design, the investigators aim to enroll 45 inpatient adults (age ≥ 65 years) to receive \"active,\" white noise (white noised played at 57-60 decibels) on one night of their stay, and \"inactive,\" white noise (white noise played at 45-50 decibels) on an alternate night. Three major primary outcomes will be investigated - 1) objective sleep duration as measured using actigraphy, 2)objectively measured sleep fragmentation using actigraphy, and 3) subjective sleep quality using the Richards Campbell Sleep Questionnaire. Secondary outcomes will include sound level changes in the room (measured using sound meters), as well as morning blood glucose (for diabetic\u002Fprediabetic patients) and blood pressure measurements. Delirium will be measured twice daily through the inpatient stay in a secondary analysis to compare levels of sleep fragmentation to delirium incidence.",[158,159,160,161],"White Noise","Sleep","Sleep Fragmentation","Sleep Duration","2024-01-22",{"date":164,"type":36},"2024-01-24",{"date":166,"type":36},"2022-07-28",{"date":168,"type":21},"2027-02-01",{"name":42,"class":43},""]